Long-acting therapies are anticipated to drive the human immunodeficiency virus (HIV) market, according to a report by GlobalData.
Titled ‘PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2025’, the report identifies a lack of long-acting and safe treatments in the HIV market.
Existing antiretroviral therapies (ART) use a combination of anti-retroviral drugs requiring a minimum of once-daily dosing. Adherence to these ARTs is a significant concern among patients.
GlobalData's healthcare analyst David Fratoni says: "Development of long-acting therapies that require intravenous injection once-a-month might address the problem, although it may not appeal to all patients."
Pharmaceutical companies are increasing focus on addressing such unmet needs through collaborations. For example, ViiV and Janssen are developing a long-acting formulation of an integrase inhibitor (INI), cabotegravir, and non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine.
The report forecasts these long-acting formulations to replace the existing treatments. Although incarcerated and homeless patients may not find these formulations appealing, other patients who dislike taking more than one pill a day are likely to opt for such treatments, states Fratoni.